T1	PrimaryOutcome 57 104	maximum high-sensitivity cardiac troponin level
T2	PrimaryOutcome 110 190	time for C-reactive protein to reach more than 3 times the upper reference limit
T3	PrimaryOutcome 200 268	time to deterioration by 2 points on a 7-grade clinical status scale
T4	SecondaryOutcome 356 419	the percentage of participants requiring mechanical ventilation
T5	SecondaryOutcome 425 444	all-cause mortality
T6	SecondaryOutcome 454 511	number, type, severity, and seriousness of adverse events
T7	PrimaryOutcome 783 875	difference in maximal high-sensitivity cardiac troponin (hs cTn) levels between the 2 groups
T8	PrimaryOutcome 884 974	time for C-reactive protein to reach levels greater than 3 times the upper reference limit
T10	SecondaryOutcome 1865 1924	percentage of participants requiring mechanical ventilation
T11	SecondaryOutcome 1926 1945	all-cause mortality
T12	TimeFrame 1946 1969	at the end of follow-up
R2	MeasuredAt Arg1:T11 Arg2:T12	
T13	SecondaryOutcome 1979 2079	number, type, severity, and seriousness of total adverse events and treatment-related adverse events
T14	PrimaryOutcome 1028 1072	time from baseline to clinical deterioration
T15	OutcomeDefinition 1087 1251	2-grade increase on an ordinal clinical scale, based on the World Health Organization R&D Blueprint Ordinal Clinical Scale,9 as used in previously published studies
T9	TimeFrame 1278 1360	3 weeks after randomization or until hospital discharge (whichever occurred first)
R1	DefinedAs Arg1:T14 Arg2:T15	
R3	MeasuredAt Arg1:T14 Arg2:T9	
